Paratek Pharmaceuticals up as key drug added to China's reimbursement list
18/01/2023 13:25
** Shares of drug developer Paratek Pharmaceuticals Inc
PRTK.O rise 8.2% to $2.51 premarket
** Co says its sole commercial product, Nuzyra, has been
added to China's list of drugs eligible for reimbursement by
central government agencies
** Nuzyra is approved in China for treatment of
community-acquired bacterial pneumonia and acute bacterial skin
and skin structure infections - PRTK
** Zai Lab Ltd ZLAB.O has taken a license for rights to
NUZYRA in China from PRTK
** PRTK fell ~48% in the past 12 months
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million